The Serum Institute of India (SII) is set to manufacture clinical trial doses of an experimental Ebola vaccine being developed by the University of Oxford, after the Coalition for Epidemic Preparedness Innovations (CEPI) announced fresh funding to accelerate efforts against the rapidly spreading Bundibugyo ebolavirus outbreak in Africa.
CEPI said it has committed up to $8.6 million to support preclinical testing and early-stage development of the Oxford vaccine candidate, with manufacturing of clinical-grade doses to be carried out by Pune-based SII.